Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Pankaj Patel, chairman and managing director of India's fifth-largest firm Cadila Healthcare expresses an unswerving support for growth through partnerships. Riding on an early partnership with Swiss firm Nycomed and lucrative opportunities in niche segments like vaccines, Cadila's growth has been extraordinary - 18-fold growth in the last 15 years.

You may also be interested in...



Indian Pharma Should Give Up Their "Yogic" Ways To Win Global Markets

Indian Pharma Should Give Up Their "Yogic" Ways To Win Global Markets

In order to gain a respectable rank on the global map, realignment of forces among Indian pharma is an imperative, Department Of Pharmaceuticals Joint Secretary Chaudhry exhorted Nov. 3 at the annual Pharma Summit organized by the Confederation of Indian Industry.

Hospira Hinges Emerging Market Success On Scale And Differentiation

Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel